Equivalence of cisplatin and carboplatin-based chemoradiation for locally advanced squamous cell carcinoma of the head and neck: A matched-pair analysis

Wilkins, Anna; Rosenfelder, N.; Schick, Ulrike; Gupta, Sweety; Thway, Khin; Nutting, Chris; Harrington, Kevin; Newbold, Kate; Bhide, S.

doi:10.1016/j.oraloncology.2013.02.004

Cited by 28 publications

(32 citation statements)

References 15 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Cetuximab appeared to have an excellent toxicity profile, similar to RT alone, as well as similar QOL (28). This contrasts with publications implicating concurrent chemotherapy in long-term dysphagia (24,25).…”

Section: Discussionmentioning

confidence: 99%

“…The chemotherapy in our institutional phase II trials was weekly carboplatin and paclitaxel, with the hope that the addition of a taxane would improve outcomes. Several studies have demonstrated the equivalence of high dose cisplatin (Q3 weeks) and weekly regimens, including carboplatin regimens, with regard to patient outcome with less toxicity for patients treated weekly (27,28). While the older RTOG studies, such as 1016, used concurrent high-dose cisplatin in the chemotherapy arm, more recent NRG/RTOG studies have used weekly low-dose cisplatin (protocols RTOG 1221 and 1216) as they are widely used in the community and reduce toxicity.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Comparisons of dysphagia and quality of life (QOL) in comparable patients with HPV-positive oropharyngeal cancer receiving chemo-irradiation or cetuximab-irradiation

et al. 2016

View full text Add to dashboard Cite

Purpose Compare functional outcomes of radiotherapy (RT) concurrent with cetuximab (cet-RT) or with chemotherapy (chemo-RT) for comparable, good prognosis patients with Human Papillomavirus related (HPV+) oropharyngeal cancer (OPC). Methods Outcomes of patients with stage III/IV HPV+ OPC patients with minimal smoking history and non-T4/N3/N2C, treated on prospective protocol of RT concurrent with cetuximab (cet-RT), were compared to similar patients on prospective chemo-RT protocols. In both groups, videofluoroscopy (VF), observer rated dysphagia (ORD), and validated QOL questionnaires: Xerostomia Questionnaire (XQ), Head and Neck QOL, and University of Washington QOL, were performed periodically and compared to pretreatment. Mixed effects models with adjustment for baseline assessed differences between groups. Results 26 cet-RT patients were compared to 27 chemo-RT patients with similar baseline characteristics. In the chemo-RT group, no recurrences occurred. In the cet-RT group, 1 patient had persistent microscopic disease on salvage neck dissection and 1 distant failure. Both groups had mild VF-based swallowing dysfunction pre-treatment, worsened at 3 months (P<0.02) and persisted at 12 months, not differing between groups (P>0.11). For both groups ORD was very low pretreatment, worsened at 3 months and improved at 12 months, without differences between treatment groups (P=0.26). QOL Summary and domain scores for eating were good pretreatment, worse at 3 mo, and then improved to near baseline at 12 months, without differences between the groups in any QOL domains (P>0.10). Conclusion Both groups had excellent clinical outcomes without significant differences in objective or subjective functions. These data question using cetuximab instead of chemotherapy for treatment de-intensification for HPV+ OPC.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Comparisons of dysphagia and quality of life (QOL) in comparable patients with HPV-positive oropharyngeal cancer receiving chemo-irradiation or cetuximab-irradiation

et al. 2016

View full text Add to dashboard Cite

show abstract

“…Details of the trial protocols can be found in the relevant publications (14)(15)(16), Table 1 and the Supplementary Data (available online at www.redjournal .org). Patients <71 years old with stage III or IV HNSCC and all those with nasopharyngeal cancer received ICC (2 cycles cisplatin and 5-fluorouracil) followed by CRT (cisplatin days 1 and 29); the regimens have previously been described in detail (17). Patients in the unknown primary trial did not receive ICC, and CRT was limited to those with extracapsular extension after neck dissection.…”

Section: Methodsmentioning

confidence: 99%

Evaluation of the Risk of Grade 3 Oral and Pharyngeal Dysphagia Using Atlas-Based Method and Multivariate Analyses of Individual Patient Dose Distributions

Otter

Schick

Gulliford

et al. 2015

International Journal of Radiation Oncology*Biology*Physics

View full text Add to dashboard Cite

“…Six studies [10][11][12][13][14]20] reported the data of 3-year OS, which included 369 patients in the cisplatin group and 361 patients in the carboplatin group. The 3-year OS for the cisplatin group was statistically similar to that of the carboplatin group (HR=0.77, 95%CI, 0.58 to 1.03; P=0.08) (Figure 2A).…”

Section: Overall Survivalmentioning

confidence: 99%

“…The tolerability of the carboplatin-based regimen was better than that of the cisplatin-based regimen [10]. Currently, there have also been several other studies comparing the cisplatin-based regimen with the carboplatinbased regimen [11][12][13][14][15][16][17][18][19][20][21], but none of these studies were sufficiently large to demonstrate a statistically significant effect.…”

Section: Introductionmentioning

confidence: 99%

A meta-analysis comparing cisplatin-based to carboplatin-based chemotherapy in moderate to advanced squamous cell carcinoma of head and neck (SCCHN).

Guan

Zhang

et al. 2015

JCO

View full text Add to dashboard Cite

Purpose: This study was performed to compare the efficacies and toxicities of cisplatin (CDDP)-and carboplatin (CBDCA)-based chemotherapy (CT) in patients with SCCHN. Methods: The search strategy included Pubmed, Science Direct, the Cochrane Library, and the China National Knowledge Internet Web. Statistical analyses were performed using RevMan 5.2. The primary endpoint was overall survival (OS) with secondary endpoints of locoregional control (LRC) and grade≥3 toxicity. Results: Overall, 12 studies and 1165 patients were included. CDDP-based CT significantly improved 5-year OS (HR=0.67, 95% CI, 0.49 to 0.91; P=0.01) compared to the CBDCA group. No difference in the 3-year OS/LRC was observed, but a subgroup analysis showed a better 3-year OS in the CDDP arm for non-nasopharynx carcinoma (non-NPC) SCCHN (HR=0.66, 95% CI, 0.48 to 0.91; P=0.01). The CDDPbased CT was associated with more gastrointestinal toxicities (RR=4.58; P=0.005) and nephrotoxicity (4/110=3.6%) compared to the CBDCA group, but fewer anemia, leukopenia and thrombocytopenia with RRs of 0.27, 0.71, and 0.28 respectively. Conclusions: Patients with CDDP-based CT can achieve a higher OS, but there is no significant difference in LRC. The CDDP-based CT is associated with fewer hematological toxicities but more gastrointestinal toxicities and nephrotoxicity compared to the CBDCA arm.

show abstract

Equivalence of cisplatin and carboplatin-based chemoradiation for locally advanced squamous cell carcinoma of the head and neck: A matched-pair analysis

Cited by 28 publications

References 15 publications

Comparisons of dysphagia and quality of life (QOL) in comparable patients with HPV-positive oropharyngeal cancer receiving chemo-irradiation or cetuximab-irradiation

Comparisons of dysphagia and quality of life (QOL) in comparable patients with HPV-positive oropharyngeal cancer receiving chemo-irradiation or cetuximab-irradiation

Evaluation of the Risk of Grade 3 Oral and Pharyngeal Dysphagia Using Atlas-Based Method and Multivariate Analyses of Individual Patient Dose Distributions

A meta-analysis comparing cisplatin-based to carboplatin-based chemotherapy in moderate to advanced squamous cell carcinoma of head and neck (SCCHN).

Contact Info

Product

Resources

About